Long-term outcomes after neoadjuvant trastuzumab and chemotherapy for HER2+breast cancer

被引：2
|
作者：
Gropper, A.
Burstein, H. J.
Harris, L.
Anderson, K. S.
Gold, J. M.
Younger, W. J.
Bunnell, C. A.
Najita, J. S.
Winer, E. P.
Mayer, E. L.
机构：
[1] Harvard Univ, Sch Med, Boston, MA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Yale Univ, Sch Med, Yale Comprehens Canc Ctr, New Haven, CT USA
[4] Mt Kisco Med Grp, Mt Kisco, NY USA
[5] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e11074
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11074
引用
收藏
页数：1
相关论文
共 50 条
  • [1] COST-UTILITY ANALYSIS OF NEOADJUVANT CHEMOTHERAPY WITH PERTUZUMAB, TRASTUZUMAB AND DOCETAXEL IN PATIENTS WITH HER2+BREAST CANCER IN SPAINCO ST-UTILITY ANALYSIS OF NEOADJUVANT CHEMOTHERAPY WITH PERTUZUMAB, TRASTUZUMAB AND DOCETAXEL IN PATIENTS WITH HER2+BREAST CANCER IN SPAIN
    Colomer, R.
    Ciruelos, E.
    De la Haba, J.
    Martin, M.
    De Salas-Cansado, M.
    Munoz-Molina, B.
    Albanell, J.
    VALUE IN HEALTH, 2016, 19 (07) : A740 - A740
  • [2] Adjuvant and neoadjuvant trastuzumab in combination with vinorelbine for HER2+breast cancer.
    Esfahani, Khashayar
    Ferrario, Cristiano
    Le, Philippe
    Panasci, Lawrence C.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Long-term Outcomes of Neoadjuvant Treatment of HER2-Positive Breast Cancer
    Zhang, Bingnan
    Hurvitz, Sara
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (07) : 520 - 530
  • [4] Long-Term Follow-Up After Preoperative Trastuzumab and Chemotherapy for HER2-Overexpressing Breast Cancer
    Mayer, Erica L.
    Gropper, Adrienne B.
    Harris, Lyndsay
    Gold, Julie M.
    Parker, Leroy
    Kuter, Irene
    Come, Steven
    Najita, Julie S.
    Guo, Hao
    Winer, Eric P.
    Burstein, Harold J.
    CLINICAL BREAST CANCER, 2015, 15 (01) : 24 - 30
  • [5] Pathological response after neoadjuvant chemotherapy and long-term outcomes among very young women with HER2 negative breast cancer
    Valencia, Fernando
    Laboriano, Jorge
    Chirinos, Luis A.
    Gomez, Henry L.
    CANCER RESEARCH, 2021, 81 (04)
  • [6] A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+Breast Cancer
    Veeraraghavan, Jamunarani
    Gutierrez, Carolina
    De Angelis, Carmine
    Davis, Robert
    Wang, Tao
    Pascual, Tomas
    Selenica, Pier
    Sanchez, Katherine
    Nitta, Hiroaki
    Kapadia, Monesh
    Pavlick, Anne C.
    Galvan, Patricia
    Rexer, Brent
    Forero-Torres, Andres
    Nanda, Rita
    Storniolo, Anna M.
    Krop, Ian E.
    Goetz, Matthew P.
    Nangia, Julie R.
    Wolff, Antonio C.
    Weigelt, Britta
    Reis-Filho, Jorge S.
    Hilsenbeck, Susan G.
    Prat, Aleix
    Osborne, C. Kent
    Schiff, Rachel
    Rimawi, Mothaffar F.
    CLINICAL CANCER RESEARCH, 2023, 29 (16) : 3101 - 3109
  • [7] Clinical Characteristics of Long-term Survivors of Metastatic HER2+Breast Cancer
    Goldbach, Macy
    Burkbauer, Laura
    Keele, Luke
    Nazarian, Susanna
    Rothman, Jami
    Tchou, Julia
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 2) : S466 - S466
  • [8] The Long-HER study: Clinical and molecular analysis of advanced HER2+breast cancer treated with trastuzumab and associated to long-term survival.
    Espinosa, Enrique
    Gamez-Pozo, Angelo
    Perez Carrion, Ramon Maria
    Manso, Luis
    Crespo, Carmen
    Mendiola, Cesar
    Alvarez, Isabel
    Margeli, Mireia
    Bayo, Juan L.
    Gonzalez, Xavier
    Santaballa, Ana
    Ciruelos, Eva
    Angel Cabrera, Miguel
    Anton, Antonio
    Catalan, Gustavo
    Alvarez Gallego, Jose Valero
    Miramon, Jose
    Lopez Vacas, Rocio
    Zamora, Pilar
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] The Pathological Response of Her2+Breast Cancer with Neoadjuvant Chemotherapy and Radiation Therapy
    Chao, M.
    Baker, C.
    Jassal, S.
    Law, M.
    Bevington, E.
    Stoney, D.
    Zantuck, N.
    Chew, G.
    Loh, S. W.
    Hyett, A.
    Guerrieri, M.
    Ng, M.
    Cokelek, M.
    Neoh, D.
    Yong, C.
    Ho, H.
    Tacey, M.
    Joon, D. Lim
    Khor, R.
    Foroudi, F.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E17 - E17
  • [10] Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+breast cancer
    Lammers, Philip E.
    Dank, Magdolna
    Masetti, Riccardo
    Abbas, Richat
    Hilton, Fiona
    Coppola, Jennifer
    Jacobs, Ira
    BRITISH JOURNAL OF CANCER, 2018, 119 (03) : 266 - 273
12345